HIV TAT Protein Transduction Domain Mediated Cell Binding and Intracellular Delivery of Nanoparticles.
Intracellular delivery of non-transported therapeutic agents has traditionally been thought possible only for low molecular weight (<500 DA) hydrophobic molecules. Higher molecular weight agents including oligonucleotides, proteins, DNA, liposomes, and nanoparticles do not readily enter the cytoplasm. However, the human immunodeficiency virus (HIV) trans-acting transcriptional activator (TAT) protein enters the cytosol by way of an 11 amino acid cationic peptide (TATp). When this cationic sequence is attached to a variety of small pharmacological agents, including paramagnetic ions[1,2] and proteins,[3-6] they are delivered into cells. Further, TATp modification of large cargo, such as proteins, polymers, and nanoparticles, may enable them to internalize into cells as well. The size limitations for cargo delivered by a single TATp are currently undetermined, but multiple TATp attached to polymers, nanoparticles, liposomes, and phage can definitely mediate their internalization. This process appears to follow an endocytotic or potocytic pathway and does not directly transfer the cargo into the cytoplasm of the cell. Here we review recent publications in which multiple TATp have been attached to and resulted in the successful intracellular delivery of nanoparticles.
Mackay
J Andrew
JA
Joint Graduate Group in Bioengineering, University of California at San Francisco and Berkeley, San Francisco, California, USA.
Szoka
Francis C
FC
Bioconjug Chem. 2002 Mar-Apr;13(2):264-8
11906263
Biomacromolecules. 2001 Summer;2(2):362-8
11749193
J Biol Chem. 1997 Apr 25;272(17):11313-20
9111037
Nat Biotechnol. 2000 Apr;18(4):410-4
10748521
Biochem Biophys Res Commun. 2002 Feb 22;291(2):367-71
11846414
Nat Biotechnol. 2001 Jul;19(7):640-4
11433275
Trends Pharmacol Sci. 2000 Mar;21(3):99-103
10689363
J Biol Chem. 2001 Jul 13;276(28):26204-10
11346640
J Biol Chem. 1997 Jun 20;272(25):16010-7
9188504
Nat Biotechnol. 2001 Dec;19(12):1173-6
11731788
J Biol Chem. 2002 Jan 25;277(4):2437-43
11711547
Bioconjug Chem. 2000 May-Jun;11(3):301-5
10821645
Gene Ther. 2002 Nov;9(21):1422-8
12378404
Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8786-91
11438707
Trends Pharmacol Sci. 2000 Feb;21(2):45-8
10664605
EMBO J. 1991 Jul;10(7):1733-9
2050110
Biochemistry. 2002 Jun 25;41(25):7925-30
12069581
Biochem Pharmacol. 1999 Apr 1;57(7):775-83
10075083
Cell Mol Biol Lett. 2002;7(2):265-7
12097943
Bioconjug Chem. 1998 Sep-Oct;9(5):612-7
9736495
Science. 1999 Sep 3;285(5433):1569-72
10477521
Eur J Biochem. 2002 Jan;269(2):494-501
11856307
Mol Pharmacol. 2002 Oct;62(4):864-72
12237333
J Biol Chem. 2001 Feb 2;276(5):3254-61
11024024
J Biol Chem. 2003 Jan 3;278(1):585-90
12411431
J Biol Chem. 2002 Oct 11;277(41):38877-83
12163493
J Clin Invest. 2001 Aug;108(4):503-10
11518721
AIDS. 1997 Oct;11(12):1421-31
9342064
J Biol Chem. 1999 Oct 1;274(40):28198-205
10497173
J Biol Chem. 1996 Jul 26;271(30):18188-93
8663410
Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13003-8
11087855
Bioconjug Chem. 1999 Mar-Apr;10(2):186-91
10077466
Nat Biotechnol. 2001 Aug;19(8):713-4
11479552
Curr Opin Biotechnol. 2000 Oct;11(5):461-6
11024364
Bioconjug Chem. 2000 Nov-Dec;11(6):762-71
11087323
FEBS Lett. 1999 Sep 24;458(3):383-6
10570945
Bioconjug Chem. 2002 Jul-Aug;13(4):840-4
12121140
Mol Ther. 2000 Oct;2(4):339-47
11020349
J Immunol Methods. 2001 Oct 1;256(1-2):89-105
11516758